- Home
- RENB vs CCEL Comparison
RENB vs CCEL Comparison
Compare RENB & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- CCEL
- Stock Information
- Founded
- RENB 2011
- CCEL 1989
- Country
- RENB United States
- CCEL United States
- Employees
- RENB N/A
- CCEL N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- RENB Health Care
- CCEL Health Care
- Exchange
- RENB Nasdaq
- CCEL Nasdaq
- Market Cap
- RENB 61.0M
- CCEL 51.9M
- IPO Year
- RENB N/A
- CCEL 1997
- Fundamental
- Price
- RENB $0.32
- CCEL $5.05
- Analyst Decision
- RENB
- CCEL Strong Buy
- Analyst Count
- RENB 0
- CCEL 1
- Target Price
- RENB N/A
- CCEL $8.50
- AVG Volume (30 Days)
- RENB 683.6K
- CCEL 9.9K
- Earning Date
- RENB 05-19-2025
- CCEL 04-15-2025
- Dividend Yield
- RENB N/A
- CCEL 4.96%
- EPS Growth
- RENB N/A
- CCEL N/A
- EPS
- RENB N/A
- CCEL 0.01
- Revenue
- RENB N/A
- CCEL $32,102,750.00
- Revenue This Year
- RENB N/A
- CCEL $2.49
- Revenue Next Year
- RENB N/A
- CCEL $0.95
- P/E Ratio
- RENB N/A
- CCEL $558.76
- Revenue Growth
- RENB N/A
- CCEL 2.33
- 52 Week Low
- RENB $0.29
- CCEL $4.75
- 52 Week High
- RENB $2.34
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- RENB 37.38
- CCEL 38.04
- Support Level
- RENB $0.29
- CCEL $4.80
- Resistance Level
- RENB $0.35
- CCEL $5.10
- Average True Range (ATR)
- RENB 0.05
- CCEL 0.29
- MACD
- RENB 0.01
- CCEL -0.00
- Stochastic Oscillator
- RENB 18.83
- CCEL 25.00
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.